AstraZeneca hits record high for fourth session in a row
Updates shares in paragraph 1, adds details throughout
** Shares of AstraZeneca AZN.L rise as much as 1.13% to 130.48 pounds
** Stock hits a record high for the fourth-straight session, taking its market capitalisation to 202.24 bln pounds ($259.78 bln)
** AZN on Wednesday convinced a U.S. judge to overturn a $107.5 million jury verdict for infringing PfizerPFE.N subsidiary Wyeth's cancer-drug patents
** On Thursday, co separately announcedthe U.S. FDA granted its cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer
** Says the date for the FDA's regulatory decision is expected in Q4
** Also late on Wednesday, global investor Sorosraised its stake in AZN by 512.9%, a filing showed
** As of last close, stock up 21.7% YTD
($1 = 0.7785 pounds)
Reporting by DhanushVignesh Babu in Bengaluru
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
